Mazowiecki Szpital Onkologiczny

Wieliszew 05-135

2 studies enrolling now · 8 studies all time

What they study most

Advanced or Inoperable Gastric Cancer, First Line Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Metastatic Breast Cancer, Metastatic Urothelial Cancer, Non-Muscle Invasive Bladder Neoplasms, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Metastatic, Urothelial Carcinoma

Studies at this site

• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Running, not enrolling
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer — Completed
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer — Completed
• Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) — Completed